Hepatitis

  • Most Topular Stories

  • Immunization interventions to interrupt hepatitis B virus mother-to-child transmission: a meta-analysis of randomized controlled trials

    MedWorm: Hepatitis B
    19 Dec 2014 | 3:00 pm
    Conclusions: The long-term protective effect of pregnant women injected with hepatitis B immunoglobulin during pregnancy should be further validated by large-scale randomized trials. Newborns of pregnant women who carried HBV should undergo a passive-active immunization strategy. (Source: Epidemiologic Perspectives and Innovations)MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
  • Hepatitis C Treatment Wins Approval, but Price Relief May Be Limited - New York Times

    hepatitis - Google News
    19 Dec 2014 | 5:39 pm
    Wall Street JournalHepatitis C Treatment Wins Approval, but Price Relief May Be LimitedNew York TimesA new treatment for hepatitis C developed by AbbVie won approval from the Food and Drug Administration on Friday, setting the stage for a marketing battle with Gilead Sciences, whose two new drugs for the disease have drawn an outcry about the high FDA Approves AbbVie Combo Hepatitis C TreatmentABC NewsUS FDA approves AbbVie hepatitis C drug, costs $83319 for 12 weeksReutersFDA Approves AbbVie's Hepatitis TreatmentWall Street JournalBoston Globe -FDA.gov -San Jose Mercury Newsall…
  • Hepatitis C Quiz

    About.com Hepatitis: What's Hot Now
    hepatitis.guide@about.com
    19 Dec 2014 | 3:13 am
    Do you understand the basics of hepatitis C? Take this short quiz to test your knowledge on all the essential hepatitis C information, including symptoms, diagnosis, treatment and prevention.
  • What Is Serum Albumin?

    About.com Hepatitis: Most Popular Articles
    19 Dec 2014 | 4:30 am
    Serum albumin is a protein in the blood which can help determine liver disease like cirrhosis. Here's a brief description of how doctors can test for serum albumin and interpret this liver function test.
  • Daclatasvir Gets Denied

    Hepatitis Central
    The Editors at Hepatitis Central
    3 Dec 2014 | 8:50 am
    FDA turns down B-MS hepatitis C drug daclatasvir World News | November 26, 2014 By Kevin Grogan US regulators have turned down Bristol-Myers Squibb’s New Drug Application for daclatasvir in combination with other hepatitis C drugs. The Food and Drug Administration has issued a complete response letter on daclatasvir, requesting additional data for the NS5A complex inhibitor, in combination with other antivirals. The situation is a little complicated given that the initial daclatasvir NDA, which focused on its use in combination with asunaprevir, an NS3/4A protease inhibitor, was withdrawn…
  • add this feed to my.Alltop

    MedWorm: Hepatitis B

  • Immunization interventions to interrupt hepatitis B virus mother-to-child transmission: a meta-analysis of randomized controlled trials

    19 Dec 2014 | 3:00 pm
    Conclusions: The long-term protective effect of pregnant women injected with hepatitis B immunoglobulin during pregnancy should be further validated by large-scale randomized trials. Newborns of pregnant women who carried HBV should undergo a passive-active immunization strategy. (Source: Epidemiologic Perspectives and Innovations)MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.
  • Old and new adjuvants for hepatitis B vaccines

    18 Dec 2014 | 3:00 pm
    Abstract The safety and immunogenicity profiles of currently available recombinant hepatitis B vaccines are excellent. However, it remains a real challenge to induce protective immunity in the target groups that respond poorly or not at all to conventional vaccines. Ideally, a hepatitis B vaccine can be developed that conveys lifelong protection against infection rapidly after the injection of a single dose. Although this goal is far from being reached, important improvements have been made. Novel vaccine adjuvants have been developed that enhance the immunogenicity of recombinant hepatitis B…
  • Mouse models for therapeutic vaccination against hepatitis B virus

    18 Dec 2014 | 3:00 pm
    In conclusion, a variety of mouse models for persistent HBV infection are available suitable for preclinical efficacy evaluations of therapeutic vaccination strategies against HBV. (Source: Medical Microbiology and Immunology)
  • Risk factors for hepatocellular carcinoma in Caucasian patients with non‐viral cirrhosis: the importance of prior obesity

    18 Dec 2014 | 3:00 pm
    ConclusionsBeside diabetes, male gender and age, a past history of obesity, but not an existing overweight, as well as exposure to tobacco and elevated transaminases were three risk factors which could improve the strategy for HCC screening in Caucasian cirrhotic patients without hepatitis B or C.This article is protected by copyright. All rights reserved. (Source: Liver International)
  • Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives

    18 Dec 2014 | 3:00 pm
    Abstract Large-scale vaccination against hepatitis B virus (HBV) infection started in 1984 with first-generation vaccines made from plasma of chronic carriers containing HBV surface antigen (HBsAg). Thereafter, it was replaced in most countries by second-generation vaccines manufactured in yeast cells transformed with gene S encoding HBsAg. Both generations of vaccines have been applied for universal neonate and early childhood vaccination worldwide and have led to a 70–90 % decrease in chronic HBV carrier rates. However, 10–30 % of newborns from HBsAg/HBeAg-positive mothers cannot be…
 
  • add this feed to my.Alltop

    hepatitis - Google News

  • Hepatitis C Treatment Wins Approval, but Price Relief May Be Limited - New York Times

    19 Dec 2014 | 5:39 pm
    Wall Street JournalHepatitis C Treatment Wins Approval, but Price Relief May Be LimitedNew York TimesA new treatment for hepatitis C developed by AbbVie won approval from the Food and Drug Administration on Friday, setting the stage for a marketing battle with Gilead Sciences, whose two new drugs for the disease have drawn an outcry about the high FDA Approves AbbVie Combo Hepatitis C TreatmentABC NewsUS FDA approves AbbVie hepatitis C drug, costs $83319 for 12 weeksReutersFDA Approves AbbVie's Hepatitis TreatmentWall Street JournalBoston Globe -FDA.gov -San Jose Mercury Newsall…
  • AbbVie Prices Hepatitis C Drug 12% Below Gilead Rival - Businessweek

    19 Dec 2014 | 3:50 pm
    AbbVie Prices Hepatitis C Drug 12% Below Gilead RivalBusinessweekAbbVie Inc. (ABBV:US) and Enanta Pharmaceuticals Inc. (ENTA:US)'s hepatitis C combination drug will be about 12 percent cheaper than its rival from Gilead Sciences Inc. (GILD:US), setting the stage for fierce competition for patients of the liver virus.
  • AbbVie says newly approved hepatitis C treatment costs $83319 - Reuters

    19 Dec 2014 | 3:47 pm
    AbbVie says newly approved hepatitis C treatment costs $83319ReutersDec 19 (Reuters) - An AbbVie Inc spokeswoman on Friday said that the company's newly approved hepatitis C treatment will cost $83,319 for a 12-week course, coming in a bit below the price of competing treatments from Gilead Sciences Inc. U.S. health ...
  • FDA OKs '3D' Combo for Hepatitis C - MedPage Today

    19 Dec 2014 | 1:36 pm
    FDA OKs '3D' Combo for Hepatitis CMedPage TodayIt can be given with or without ribavirin, a nonspecific antiviral long used to treat HCV, the FDA said. "The new generation of therapeutics for hepatitis C virus is changing the treatment paradigm for Americans living with the disease," according to
  • US FDA approves AbbVie all-oral hepatitis C treatment - Reuters

    19 Dec 2014 | 12:22 pm
    US FDA approves AbbVie all-oral hepatitis C treatmentReuters(Reuters) - U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus. The AbbVie regimen consists of
  • add this feed to my.Alltop

    About.com Hepatitis: What's Hot Now

  • Hepatitis C Quiz

    hepatitis.guide@about.com
    19 Dec 2014 | 3:13 am
    Do you understand the basics of hepatitis C? Take this short quiz to test your knowledge on all the essential hepatitis C information, including symptoms, diagnosis, treatment and prevention.
  • HBcAb

    hepatitis.guide@about.com
    19 Dec 2014 | 3:13 am
    Definition of HBcAb. Hepatitis.
  • Sign

    hepatitis.guide@about.com
    19 Dec 2014 | 3:13 am
    Definition of sign. Hepatitis.
  • What Is Acute Liver Failure?

    hepatitis.guide@about.com
    19 Dec 2014 | 3:13 am
    Acute liver failure is a medical emergency that is rare but can result from various types of hepatitis, especially hepatitis A and hepatitis B infections.
  • What Are Hepatitis C Genotypes?

    hepatitis.guide@about.com
    19 Dec 2014 | 3:13 am
    Each hepatitis C virus is actually one of 6 major genotypes and 50 subtypes. Which genotype you have determines how easily you respond to treatment.
 
  • add this feed to my.Alltop

    About.com Hepatitis: Most Popular Articles

  • What Is Serum Albumin?

    19 Dec 2014 | 4:30 am
    Serum albumin is a protein in the blood which can help determine liver disease like cirrhosis. Here's a brief description of how doctors can test for serum albumin and interpret this liver function test.
  • The Link Between Hepatitis and Liver Cancer

    19 Dec 2014 | 4:30 am
    If you’re one of those individuals who suffer from hepatitis or other forms of hepatitis, it’s very imperative to consult your physicians immediately to prevent the occurrence of serious symptoms like liver cancer that can lead to sudden death.
  • What Is Hepatitis C Infection

    19 Dec 2014 | 4:30 am
    Hepatitis C is a major cause of liver disease for almost 170 million people in the world and almost 4 million in the United States. The disease can be relatively simple for some, but for most it leads to a chronic condition of cirrhosis and other complications.
  • What to Do When You Get a Report Saying That...

    19 Dec 2014 | 4:30 am
    It is a difficult phase to accept the fact that you are suffering from hepatitis. Consult your doctor as he will help you to cope the situation in a better way.
  • What It Means if Your Doctor Orders an HBsAG Test

    19 Dec 2014 | 4:30 am
    Definition of HBsAG. Hepatitis.
  • add this feed to my.Alltop

    Hepatitis Central

  • Daclatasvir Gets Denied

    The Editors at Hepatitis Central
    3 Dec 2014 | 8:50 am
    FDA turns down B-MS hepatitis C drug daclatasvir World News | November 26, 2014 By Kevin Grogan US regulators have turned down Bristol-Myers Squibb’s New Drug Application for daclatasvir in combination with other hepatitis C drugs. The Food and Drug Administration has issued a complete response letter on daclatasvir, requesting additional data for the NS5A complex inhibitor, in combination with other antivirals. The situation is a little complicated given that the initial daclatasvir NDA, which focused on its use in combination with asunaprevir, an NS3/4A protease inhibitor, was withdrawn…
  • Hold Onto Your Hats: Has a Vaccine for Hepatitis C Arrived?

    The Editors at Hepatitis Central
    25 Nov 2014 | 11:33 am
    “Promising” results in Oxford trials of Hepatitis C vaccine Oxford team develop first hepatitis C vaccine to be trialled on human volunteers By Suzie Marshall,  November22,  2014 A new vaccine developed by researchers at the University of Oxford has generated a strong immune response against the Hepatitis C virus in human volunteers. The vaccine is the first Hepatitis C inoculation to reach this stage of clinical trials, and the results have been promising. The 15 healthy human volunteers who took part in the phase 1 safety trial all responded positively. Continue reading this…
  • A Win for Liver Transplant Patients with Hepatitis C

    The Editors at Hepatitis Central
    25 Nov 2014 | 11:23 am
    Europe gives green light to AbbVie hepatitis C drugs, others (Reuters) – European regulators recommended approval for two drugs made by AbbVie to treat hepatitis C, both of which belong to a new generation of medicines that have proved effective in treating a condition that is the most common cause of liver transplants in Europe. Dasabuvir, known commercially as Exviera, and a combination therapy called Viekirax, gave physicians additional treatment options with high cure rates, the European Medicines Agency said on Friday. Continue reading this entire article:…
  • Second All-Oral Hep C Treatment Available: Less Expensive

    admin
    13 Nov 2014 | 7:16 am
    J&J Wins U.S. Approval for Hepatitis C Combo With Gilead By Anna Edney Johnson & Johnson (JNJ) won U.S. approval for its hepatitis C drug Olysio to be used in combination with Gilead Sciences Inc. (GILD)’s Sovaldi, making it the second all-oral treatment available for the most common form of the virus. The Food and Drug Administration cleared the once-daily treatment for patients with hepatitis C genotype 1, J&J said yesterday in a statement. The combination allows Olysio to be used without the standard therapies including interferon, an injection that sometimes has flu-like…
  • Harvoni Is Here: The Once-a-Day, Single Hep C Pill

    Nicole Cutler L.Ac.
    12 Nov 2014 | 9:21 am
    The Hepatitis C community has been waiting a long time for a miracle – and Harvoni nearly fits the bill. Approved on October 10, 2014, Harvoni became the first Hepatitis C drug approved by the U.S. Food and Drug Administration (FDA) that does not require the patient to also take interferon or ribavirin. In the form of a once daily pill, Harvoni seems to be the medication many struggling with this infectious disease had been hoping for. Of course, it shouldn’t be surprising that a drug with such fanfare comes with a steep price tag. The U.S. Centers for Disease Control and Prevention…
 
  • add this feed to my.Alltop

    Hepatitis News

  • AbbVie to Sell Hepatitis C Drug at 12% Discount to Gilead Rival

    19 Dec 2014 | 10:43 pm
    … . and Enanta Pharmaceuticals Inc.’s hepatitis C combination drug will be … necessitating a costly liver transplant. Hepatitis C is transmitted through infected … , which is part of older hepatitis C regimens. Foster City, California-based … Human Use gave AbbVie’s hepatitis C combination treatment, called Viekirax …
  • US FDA approves AbbVie hepatitis C drug, costs $109,673 for 12 weeks

    19 Dec 2014 | 9:23 pm
    … 's all-oral treatment for hepatitis C, and the company said … , the most common type of hepatitis C and the most difficult …
  • FDA approves AbbVie combo hepatitis C treatment 

    19 Dec 2014 | 7:52 pm
    … , New Jersey — Patients with chronic hepatitis C have a new option … ;s among several new pill-only hepatitis C treatments that are big … million Americans are infected with hepatitis C, which generally doesn… new generation of therapeutics for hepatitis C virus is changing the …
  • AbbVie Inc.'s hepatitis C combination treatment approved by Food and Drug Administration

    19 Dec 2014 | 6:54 pm
    … ;s among several new pill-only hepatitis C treatments that are big … million Americans are infected with hepatitis C, which generally doesn… new generation of therapeutics for hepatitis C virus is changing the … 2,308 participants with chronic hepatitis C, some of them with …
  • FDA Backs AbbVie's Hepatitis Treatment

    19 Dec 2014 | 6:37 pm
    … .’s new multidrug regimen for hepatitis C, the latest in a … the most common subtype of hepatitis C in the U.S …
  • add this feed to my.Alltop

    Hepatitis C Treatment News

  • AbbVie to Sell Hepatitis C Drug at 12% Discount to Gilead Rival

    19 Dec 2014 | 10:43 pm
    … Viekira Pak is an all-oral medication that doesn’t require … pills a day for 12 weeks, compared with one pill … and development, said in an interview before the FDA decision. … Human Use gave AbbVie’s hepatitis C combination treatment, called Viekirax there, …
  • US FDA approves AbbVie hepatitis C drug, costs $109,673 for 12 weeks

    19 Dec 2014 | 9:23 pm
    … approved AbbVie's all-oral treatment for hepatitis C, and the company said … four different anti-viral drugs to be taken as three pills in the … a 12 week treatment. Enanta Pharmaceuticals Inc, which helped develop the Abbvie …
  • FDA approves AbbVie combo hepatitis C treatment 

    19 Dec 2014 | 7:52 pm
    … of a combination treatment developed by AbbVie. The … combination pill, which contains the antiviral drugs ombitasvir, … hepatitis C treatments that are big improvements over earlier treatments … treatment regimen involves taking two of the combination pills …
  • AbbVie Inc.'s hepatitis C combination treatment approved by Food and Drug Administration

    19 Dec 2014 | 6:54 pm
    … of a combination treatment developed by AbbVie. The … combination pill, which contains the antiviral drugs ombitasvir, … hepatitis C treatments that are big improvements over earlier treatments … treatment regimen involves taking two of the combination pills …
  • FDA Backs AbbVie's Hepatitis Treatment

    19 Dec 2014 | 6:37 pm
    … new medicines that is transforming treatment of the liver disease. The … , an all-oral cocktail of several drugs that cured more than 90 … of hepatitis C in the U.S., genotype 1, in clinical trials. The …
  • add this feed to my.Alltop

    Hepatitis News

  • Incidence rates of tuberculosis in chronic hepatitis C infected...

    19 Dec 2014 | 11:13 pm
    BackgroundIt is debated whether interferon-based therapy would affect the incidence of active tuberculosis among hepatitis C virus infected patients. Although some case reports have demonstrated a possible association, the results are currently inconclusive.
  • Immunization interventions to interrupt hepatitis B virus...

    19 Dec 2014 | 7:04 pm
    BackgroundThis study aimed to determine the clinical efficacy of various immune interventions on mother-to-child transmission of hepatitis B virus .MethodsWe retrieved different immune strategies on how to prevent MTCT reported in the literature from Chinese and English electronic databases from the viewpoint of intrauterine and extrauterine prevention. Relative risk and 95% confidence interval methods were used.ResultsTwenty-five articles on intrauterine prevention and 16 on extrauterine prevention were included in the analysis.
  • FDA Approves AbbVie Combo Hepatitis C Treatment

    19 Dec 2014 | 12:50 pm
    Patients with chronic hepatitis C have a new option for treating the liver-damaging virus, with the approval of a combination treatment developed by AbbVie . The Food and Drug Administration approved the sale of a packaged treatment called Viekira Pak made by AbbVie Inc. of North Chicago , Illinois.
  • U.S. FDA approves AbbVie all-oral hepatitis C treatment

    19 Dec 2014 | 12:50 pm
    U.S. health regulators on Friday approved AbbVie's all-oral treatment for hepatitis C, providing the first competition for Gilead Sciences huge selling and expensive medicine for the liver-destroying virus. The AbbVie regimen consists of four different anti-viral drugs to be taken as three pills in the morning and one in the evening.
  • Potential treatment for nonalcoholic fatty liver disease

    19 Dec 2014 | 7:30 am
    Inhibiting a nuclear receptor in the gut could lead to a treatment for a liver disorder that affects almost 30 percent of the Western world's adult population, according to an international team of researchers. The researchers found that tempol, an antioxidant drug, and antibiotics can treat and prevent nonalcoholic fatty liver disease in mice that were fed a high-fat diet.
 
  • add this feed to my.Alltop

    Hepatitis Blog

  • Hamilton New Jersey Rosa’s Restaurant Hepatitis A Scare

    Bill Marler
    1 Dec 2014 | 8:19 pm
    Cristina Rojas reports that a confirmed case of hepatitis A has been traced to a food worker employed at Rosa’s Restaurant and Catering in Hamilton, officials said late Monday. Health officials warned that anyone who ate at or catered from the restaurant between Nov. 10 and Monday may be at risk for developing Hepatitis A if they have not been previously vaccinated. Unvaccinated individuals who ate there should receive an injection of immune globulin or hepatitis A vaccine. Both can prevent an infection if given within 14 days of exposure. Officials urged anyone who ate at the restaurant…
  • Red Robin Restaurant Hepatitis A Exposure Class Action lawsuit – Missouri (2014)

    Bill Marler
    28 Oct 2014 | 5:14 pm
    Springfield Missouri Health officials administered more than 5,000 doses of the hepatitis A vaccine. On May 20, 2014, health department officials learned of a food service worker at the Red Robin restaurant who had tested positive for Hepatitis A. Individuals potentially exposed to the Hepatitis A virus dined at the restaurant between May 8 and 16. Marler Clark filed a class action lawsuit against Red Robin restaurant.  The lawsuit was filed on behalf of restaurant patrons who received hepatitis A vaccinations after alleged exposure to the hepatitis A virus at the restaurant between May 8…
  • Hepatitis A Cluster in Alabama

    Bill Marler
    27 Sep 2014 | 9:29 am
    The Alabama Department of Public Health is investigating three cases of hepatitis A in Clarke County in southwest Alabama. The department says two of the cases involve people who have a history of international travel. The health department says signs of hepatitis A appear 15 to 50 days after exposure and commonly include mild fever, loss of appetite, nausea, vomiting and tiredness. The disease varies in severity from about two weeks to six weeks or more. The department says casual contact, such as at an office or school, does not transmit the virus. The risk increases when people are in…
  • 165 Sick with Hepatitis A Linked to Townsend Farms Organic Antioxidant Blend

    Bill Marler
    25 Sep 2014 | 9:52 pm
    165 people were confirmed to have become ill from hepatitis A after eating ‘Townsend Farms Organic Antioxidant Blend’ in 10 states: Arizona (24), California (80), Colorado (29), Hawaii (8), New Hampshire (1), New Jersey (1), New Mexico (11), Nevada (6), Utah (3), and Wisconsin (2). [Note: The cases reported from Wisconsin resulted from exposure to the product in California, the cases reported from New Hampshire reported fruit exposure during travel to Nevada, and the case reported in New Jersey was a household contact of a confirmed case from Colorado.] Eight of the confirmed cases were…
  • Whataburger Linked to Hepatitis A Scare

    Bill Marler
    21 Aug 2014 | 9:12 pm
    Austin Texas health officials are alerting the public about possible hepatitis A exposure at a Whataburger in Central Austin. A restaurant employee there at the 2800 Guadalupe St. location has been diagnosed with the hepatitis A virus. Hepatitis A is a contagious liver disease that is usually spread when a person ingests something that has been contaminated with the feces of an infected person, including contaminated food or water. Signs and symptoms of hepatitis A can include the following Fever Fatigue Loss of appetite Nausea Vomiting Abdominal discomfort Dark urine Clay-colored bowel…
 
  • add this feed to my.Alltop

    HCV New Drug Research

  • FDA Approves AbbVie Combo Hepatitis C Treatment

    19 Dec 2014 | 5:59 pm
    FDA News ReleaseFDA approves Viekira Pak to treat hepatitis CFor Immediate ReleaseDecember 19, 2014EspañolThe U.S. Food and Drug Administration today approved Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) to treat patients with chronic hepatitis C virus (HCV) genotype 1 infection, including those with a type of advanced liver disease called cirrhosis.Hepatitis C is a viral disease that causes inflammation of the liver that can lead to reduced liver function, liver failure or liver cancer. Most people infected with HCV have no symptoms of the…
  • In Hepatitis C, Treatment Rationing Has Already Begun

    17 Dec 2014 | 4:25 am
    To curb an estimated 6% to 11% increase in Medicare Part D spending, 3 states have already placed limitations on which patients with chronic hepatitis C are candidates for treatment with novel antiviral agents. The debate about which patients with hepatitis C are appropriate treatment candidates is a contentious issue, according to Marc G. Ghany, MD, MHSc, in an editorial published in JAMA Internal Medicine.   With nearly 30% of cirrhosis cases and 1 in 4 cases of hepatocellular carcinoma caused by hepatitis C, a clear opportunity for prevention of expensive public health…
  • 13 Dec 2014 | 3:33 am

    13 Dec 2014 | 3:33 am
    Hello folks, hope everyone is healthy and happy. I shall be away for a short time, the family is flying away to the Magic Kingdom! Nana, along with the short people will be sharing time with Mickey and his friends.See you all when I get back, be well.Tina
  • Summary from AASLD 2014 for Hepatitis C - Main points of discussion with current HCV therapy

    12 Dec 2014 | 3:56 am
    Summary from AASLD 2014 for Hepatitis C Boston 7-11 November 2014Feedback from the real-world: do HCV cure rates in real-life patient cohorts hold what clinical trials promised?Jurgen K. Rockstroh M.D., Professor of MedicineUniversity of Bonn, GermanyCorrespondence:Prof. Dr. J.K. RockstrohDepartment of Medicine IUniversity of BonnSigmund-Freud-Str. 2553105 BonnGermanyTel.: +49-228-287 16558FAX: +49-228-287 15034e-mail: juergen.rockstroh@ukb.uni-bonn.deIntroductionAfter this year EASL it appeared as if numerous interferon- and ribavirin-free DAA combinations were emerging which all promised…
  • Daclatasvir for hepatitis C: Added benefit not proven

    10 Dec 2014 | 7:23 am
    Daclatasvir for hepatitis C: Added benefit not provenThe drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this new drug offers an added benefit over the appropriate comparator therapy.The drug manufacturer presented data for patients without cirrhosis of the liver who are infected with hepatitis C virus (HCV) genotype 1, and for patients with HCV genotype 4. However, these data are…
Log in